Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study)

• Status: Completed
• Trial end date: 2019-10-07
• Target enrollment: 0
• Participant gender: All

Summary

Glucagon like Peptide -1 (GLP-1) receptor agonists are well known to stimulate glucose-induced insulin secretion and to reduce energy intake. Recent findings from animal and human studies suggest a role of GLP-1 in regulating water and salt homeostasis. GLP-1 has been shown to reduce fluid intake after an oral salt load or during a meal - pointing to a hypodipsic effect. The aim of this study is to elucidate whether these putative hypodipsic properties of GLP-1 might be of advantage in persons with an exaggerated thirst perception as is the case in patients with primary polydipsia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Basel, Switzerland
• Treatments: Dulaglutide

Criteria

Inclusion Criteria:

• Age over 18 years

• Polyuria of > 50 ml/Kg/day

• Polydipsia of > 3 liters/day

Exclusion Criteria:

• Known or probable central or nephrogenic Diabetes insipidus, expected from patient's history

• Polyuria secondary to diabetes mellitus, hypokalemia, hypercalcemia

• Pregnancy

• Previous treatment with GLP-1 agonists within the last 3 month

• History of pancreatitis

• Severe renal insufficiency (eGFR (CKD EPI) <30 ml/min/1,73 m2)

• Cancer